Developing a new liposome-based adjuvant for COVID-19 vaccines
Official title: ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
Funded at Vaccine Formulation Institute (Ch) LTD · NIH-11126499 · Data updated 2026-11-12
This study is working on a new ingredient to boost the effectiveness of COVID-19 vaccines, making them stronger and more affordable, so that more people can benefit from better protection against the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vaccine Formulation Institute (Ch) LTD NIH-funded |
| Lab location | 1 site (Plan-Les-Ouates, Switzerland) |
| Project start | September 30, 2023 |
| Project end | September 29, 2028 |
| Funding year | 2024 |
| Award (this year) | $3,488,070 |
| NIH project number | 75N93023C00048-P00001-9999-1 |
| Project ID | NIH-11126499 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of COVID-19 and may benefit from enhanced vaccine responses.
✕Less likely to help
Patients who are not at risk for COVID-19 or those who have already received effective vaccinations may not benefit from this research.
What this research studies
This research focuses on creating a novel vaccine adjuvant that enhances immune responses specifically for COVID-19 vaccines. It involves formulating a cost-effective saponin fraction within a liposome carrier to improve the vaccine's effectiveness. The project includes optimizing the formulation and conducting extensive preclinical studies to evaluate the adjuvant's safety and immunogenicity. Ultimately, the goal is to make this adjuvant widely available to the vaccine development community.
Why it matters
Potential benefit: If successful, this research could lead to more effective and affordable COVID-19 vaccines.
How similar studies have gone: Other research has shown promise in using liposome-based adjuvants for vaccine development, indicating a potential for success in this approach.
Where this research is happening
-
Vaccine Formulation Institute (Ch) LTD
Plan-Les-Ouates, Switzerland Active
Researchers
- Principal investigator: Collins, Nicolas — Vaccine Formulation Institute (Ch) LTD
- Study coordinator: Collins, Nicolas
Related research
Other NIH-funded projects on the same topics.
-
Developing new immune system boosters for tuberculosis treatment
This study is exploring new ways to boost the immune system's fight against tuberculosis by testing special compounds that help vaccines work better, and it's aimed at finding treatments that could eventually help people with this condition.
-
Developing a new liposome-based adjuvant for vaccines against SARS coronavirus
This study is working on a new, affordable ingredient to make vaccines stronger and more effective against certain viruses, with the hope that it will help create better vaccines for everyone.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.